share_log

10-Q: Q3 2024 Earnings Report

10-Q: Q3 2024 Earnings Report

10-Q：2024財年三季報
美股SEC公告 ·  2024/10/31 23:46

Moomoo AI 已提取核心訊息

Bristol-Myers Squibb reported Q3 2024 revenues of $11.9 billion, up 8% year-over-year, driven by strong performance from its Growth Portfolio and Eliquis. Net earnings were $1.2 billion with diluted EPS of $0.60, compared to $1.9 billion and $0.93 EPS in Q3 2023. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.8 billion.The company achieved significant regulatory milestones, including FDA approval of Cobenfy for schizophrenia and expanded approvals for Breyanzi in multiple indications. Operating expenses increased primarily due to recent acquisitions, with R&D expenses up 6% to $2.4 billion and amortization of acquired intangible assets rising 7% to $2.4 billion.BMS maintained strong liquidity with $7.9 billion in cash and cash equivalents while completing strategic acquisitions of Karuna, RayzeBio and Mirati. The company issued $13 billion in senior unsecured notes to partially fund these acquisitions. Operating cash flow remained robust at $10.8 billion year-to-date, supporting continued dividend payments of $3.6 billion.
Bristol-Myers Squibb reported Q3 2024 revenues of $11.9 billion, up 8% year-over-year, driven by strong performance from its Growth Portfolio and Eliquis. Net earnings were $1.2 billion with diluted EPS of $0.60, compared to $1.9 billion and $0.93 EPS in Q3 2023. The Growth Portfolio, including Opdivo, Orencia and Yervoy, saw an 18% increase in revenue to $5.8 billion.The company achieved significant regulatory milestones, including FDA approval of Cobenfy for schizophrenia and expanded approvals for Breyanzi in multiple indications. Operating expenses increased primarily due to recent acquisitions, with R&D expenses up 6% to $2.4 billion and amortization of acquired intangible assets rising 7% to $2.4 billion.BMS maintained strong liquidity with $7.9 billion in cash and cash equivalents while completing strategic acquisitions of Karuna, RayzeBio and Mirati. The company issued $13 billion in senior unsecured notes to partially fund these acquisitions. Operating cash flow remained robust at $10.8 billion year-to-date, supporting continued dividend payments of $3.6 billion.
施貴寶公佈2024年第三季度營業收入爲119億，同比增長8%，主要受到其增長投資組合和Eliquis的強勁表現推動。淨收益爲12億，攤薄後每股收益爲0.60美元，而2023年第三季度爲19億和0.93美元的每股收益。增長投資組合，包括Opdivo、Orencia和Yervoy，營業收入增長18%，達到58億。公司實現了重要的監管里程碑，包括FDA批准Cobenfy用於治療精神分裂症，並在多個適應症上擴大了對於Breyanzi的批准。營業費用主要由於近期收購而增加，研發費用增長6%，達到24億，收購無形資產的攤銷增加7%，達到24億。BMS保持強大的流動性，現金及現金等價物爲79億，同時完成了對Karuna、RayzeBio和Mirati的戰略收購。公司發行了130億的高級無擔保票據以部分資助這些收購。今年至今，營業現金流強勁，達到108億，支持持續的36億現金分紅支付。
施貴寶公佈2024年第三季度營業收入爲119億，同比增長8%，主要受到其增長投資組合和Eliquis的強勁表現推動。淨收益爲12億，攤薄後每股收益爲0.60美元，而2023年第三季度爲19億和0.93美元的每股收益。增長投資組合，包括Opdivo、Orencia和Yervoy，營業收入增長18%，達到58億。公司實現了重要的監管里程碑，包括FDA批准Cobenfy用於治療精神分裂症，並在多個適應症上擴大了對於Breyanzi的批准。營業費用主要由於近期收購而增加，研發費用增長6%，達到24億，收購無形資產的攤銷增加7%，達到24億。BMS保持強大的流動性，現金及現金等價物爲79億，同時完成了對Karuna、RayzeBio和Mirati的戰略收購。公司發行了130億的高級無擔保票據以部分資助這些收購。今年至今，營業現金流強勁，達到108億，支持持續的36億現金分紅支付。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    吉利德科學
    GILD
    -- 111.160
    阿瑪琳
    AMRN
    -- 0.467
    諾華製藥
    NVS
    -- 111.400
    強生
    JNJ
    -- 163.130
    賽諾菲安萬特
    SNY
    -- 54.910
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日